Modulation of host defense peptide-mediated human mast cell activation by LPS

Kshitij Gupta1, Hariharan Subramanian1, Hydar Ali2

  • 1Department of Pathology, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, USA.

Innate Immunity
|October 30, 2015
PubMed

Insights

New host defense peptide (HDP) derivatives, CHRG01 and FK-13, activate mast cells via Mas-related gene-X2 (MrgX2) independently of lipopolysaccharide (LPS) inhibition, offering potential for antibiotic-resistant infections.

Area of Science:

  • Immunology
  • Microbiology
  • Pharmacology

Background:

  • Host defense peptides (HDPs) like human β-defensin3 (hBD3) and cathelicidin LL-37 possess antimicrobial and immunomodulatory functions.
  • Modified peptides (CHRG01, FK-13) retain antimicrobial activity but lack immunomodulatory properties.
  • Lipopolysaccharide (LPS) from bacteria can inhibit HDPs, aiding pathogen evasion.

Purpose of the Study:

  • To investigate the mechanism by which modified HDPs (CHRG01, FK-13) interact with host cells.
  • To determine if these modified HDPs are affected by LPS inhibition.
  • To explore the therapeutic potential of LPS-resistant HDP derivatives.

Main Methods:

  • Calcium (Ca2+) mobilization assays in human mast cells.
  • Mast cell degranulation assays.
  • Assessment of peptide activity in the presence and absence of LPS.

Main Results:

  • CHRG01 and FK-13 induced Ca2+ mobilization and degranulation in human mast cells via Mas-related gene-X2 (MrgX2).
  • Unlike native hBD3 and LL-37, CHRG01 and FK-13 activity was not inhibited by LPS.
  • These findings highlight a novel LPS-resistant mechanism for HDPs.

Conclusions:

  • Modified HDPs activating MrgX2 offer a promising strategy against antibiotic-resistant infections.
  • Harnessing mast cell responses via LPS-resistant HDPs could enhance host defense.
  • Development of HDP derivatives resistant to LPS inhibition is a viable therapeutic avenue.